Electromed Stock Price and Value Analysis

Electromed (NYSE American:ELMD) in our automated value investing analysis, with the cash flow history and price comparison below.

Key Facts

Advertisement helps keep Trendshare free for most readers.

Hold-time calculator

Estimate how long you need to hold Electromed to reach your target.

Target type

ELMD Free Cash Flow Trend

Free Cash Flow trendline for ELMD
Free Cash Flow trendline for Electromed
CSV

Based on historical returns, we believe that Electromed can grow its free cash at a rate of about 6%. That's positive!

AdvantagesDisadvantagesNeutral
  • This company is making money at a decent rate.
  • This company has wild ups and downs.
  • This company is less known than others.
  • This stock looks overpriced.
  • This company pays no dividend.

Inside the ELMD Numbers

ELMD Price
(Electromed stock price per share)
$22.98
[?] ELMD Fair Price
(based on intrinsic value)
$6.60
[?] ELMD Safety Price (based on a variable margin of safety) $3.96
Try your own return

The fair price above uses a 10.1% discount rate, the long-run US stock return (10.1% geometric, 1926 to 2025, from Bessembinder's working paper, updated 2026-11-09), and 2.5% terminal growth. A higher rate suits a higher return target and gives a lower value.

Value per share:

[?] PE Ratio versus Sector 16% lower than other Healthcare stocks
[?] PE Ratio versus Industry 0% lower than other Medical Devices stocks
[?] Free Cash Flow Jitter 106%

Insider Activity Summary

No open-market insider buys or sells are recorded for the last 12 months.

This stock has short interest! This means that people have shorted it.

Why does that matter? They've made a bet that price will decrease from where they bought it. Maybe there are financial problems, or maybe there's a value play.

As of the latest analysis, there are 180,632 shares shorted. With 6,737,099 shares available for purchase and an average trading volume over the past 10 trading days of 66,650, it would take at least 2.7 days for all of the short holders to cover their shorts.

Related guides: good annual rate of return · high-yield stocks · forecasting earnings growth

Free Cash Flow by Fiscal Year

How to read this: free cash flow in plain terms, free cash flow jitter.

Each year names the SEC filer that reported it, so a change of filer shows up here.

Fiscal yearSEC filer (CIK)Free cash flow (USD millions)
2011 1488917 -1.9
2012 1488917 -1.8
2013 1488917 1.1
2014 1488917 1.3
2015 1488917 2
2016 1488917 1.4
2017 1488917 0.5
2018 1488917 1.8
2019 1488917 1.9
2020 1488917 3.4
2021 1488917 2.4
2022 1488917 -1.6
2023 1488917 0.2
2024 1488917 8.2
2025 1488917 10.6
2026 1488917 8.7

Download the yearly data as CSV.

Cash Conversion

How to read this: what free cash flow is, why earnings matter.

Over the 14 fiscal years from 2011 to 2026 with positive net income, operating cash flow totaled $46.6 million against net income of $46.6 million, or 1.00 times. Net income was negative in 2 of the 16 years, and those years are left out of the ratio.

In 2026, operating cash flow was 0.86 times net income, compared with -2.08 times for the earliest three years (2011 to 2013).

In 2026, capital expenditures were $1.3 million, 13.0% of operating cash flow of $9.7 million, which leaves an estimated $8.4 million after capex. Across the 13 years with reported capex, it averaged 18.6% of operating cash flow. This uses that year's own capital expenditures, not the five-year average behind the free cash flow table, so the two can differ.

Fiscal yearNet income (USD millions)Operating cash flow (USD millions)Capital expenditures (USD millions)Operating cash flow / net income
2011 1.1 -1.4 0.5 -1.34
2012 0.2 -1.2 0.8 -6.28
2013 -1.3 1.9 1 n/a
2014 -1.3 2.1 0.9 n/a
2015 1.1 2.8 0.5 2.55
2016 2.2 2.2 0.5 0.98
2017 2.2 1.2 0.6 0.53
2018 1.8 2.4 0.5 1.33
2019 2 2.6 1.3 1.31
2020 4.2 4.2 0.8 1.01
2021 2.4 3.1 0.3 1.30
2022 2.3 -0.7 1.4 -0.30
2023 3.2 1.3 1.6 0.42
2024 5.2 9.1 0.3 1.76
2025 7.5 11.4 0.3 1.51
2026 11.3 9.7 1.3 0.86

Where the Cash Went

How to read this: why companies buy back shares, dividend yield explained.

Over the 6 fiscal years from 2021 to 2026 with dividend or share repurchase facts, estimated free cash flow totaled $28.5 million. That estimate uses the average of up to five years of capital expenditures, not each year's own, so it is not a reported figure.

In 4 of the 6 years, cash spent repurchasing shares was at least 5% of that year's estimated free cash flow, and in those years it totaled $15.2 million. Smaller amounts are left out of this sentence because they can be shares withheld to pay employees' taxes on stock awards.

In 2026, cash spent repurchasing shares was $3.9 million, 45.1% of estimated free cash flow of $8.7 million.

Fiscal yearEstimated free cash flow (USD millions)Dividends paid (USD millions)Cash spent repurchasing shares (USD millions)Total returned (USD millions)Total as a percent of estimated free cash flow
2021 2.4 n/a 1.1 1.1 47.7%
2022 -1.6 n/a 1.4 1.4 n/a
2023 0.2 n/a 0.2 0.2 73.5%
2024 8.2 n/a 0.3 0.3 3.4%
2025 10.6 n/a 10 10 94.2%
2026 8.7 n/a 3.9 3.9 45.1%

Free cash flow here is an estimate: operating cash flow less the average of up to five years of capital expenditures. Cash spent repurchasing shares can include shares withheld to pay employees' taxes on stock awards. The entry n/a means the filings gave no usable figure, not that the amount was zero. Source: the company's annual reports to the SEC.

Revenue and Cash Margin

How to read this: earnings and margins.

Revenue was $19 million in 2011 and $73.8 million in 2026, a compound annual growth rate of 9.5% over 15 years.

Revenue rose 15.3% from 2025 to 2026.

Our estimated free cash flow was $8.7 million in 2026, 11.8% of revenue. In 2011 the estimated margin was negative 9.9%. This estimate charges each year with the average of up to five years of capital expenditures, so it is not the free cash flow the company reported.

Fiscal yearRevenue (USD millions)Estimated free cash flow (USD millions)Estimated free cash flow / revenue
2011 19 -1.9 -9.9%
2012 19.5 -1.8 -9.2%
2013 15.1 1.1 7.4%
2014 15.5 1.3 8.2%
2015 19.4 2 10.5%
2016 23 1.4 6.2%
2017 25.9 0.5 1.8%
2018 28.3 1.8 6.4%
2019 31.3 1.9 6.0%
2020 32.5 3.4 10.5%
2021 35.8 2.4 6.6%
2022 41.7 -1.6 -3.8%
2023 48.1 0.2 0.4%
2024 54.7 8.2 14.9%
2025 64 10.6 16.6%
2026 73.8 8.7 11.8%

Balance Sheet

How to read this: how debt and assets are compared, the current ratio.

In 2026, cash and equivalents were $20.4 million against total liabilities of $12.3 million, or 166.4% of total liabilities. Total liabilities include everything the company owes, not only borrowed money.

Total liabilities were 18.5% of total assets in 2026, compared with 29.5% in 2011, a decrease of 11.0 percentage points.

Stockholders equity was $54 million in 2026, compared with $14.7 million in 2011, a rise of 267.0%.

Based on our estimated free cash flow, cash flow return on invested capital (CROIC) was 25.9% in 2026. Invested capital here is total assets less cash and current liabilities.

Fiscal yearTotal assets (USD millions)Cash and equivalents (USD millions)Total liabilities (USD millions)Stockholders equity (USD millions)
2011 20.9 4.1 6.2 14.7
2012 20.9 1.7 5.8 15.1
2013 17.6 0.5 3.6 13.9
2014 15.8 1.5 3.1 12.7
2015 17.4 3.6 3.5 13.9
2016 20.6 n/a 4.2 16.4
2017 23.1 n/a 3.2 19.8
2018 27.4 n/a 4.8 22.6
2019 29.4 n/a 3.7 25.7
2020 33.2 10.5 3 30.2
2021 37.1 11.9 4.7 32.4
2022 41.4 8.2 7.2 34.2
2023 45.8 7.4 8.1 37.7
2024 52.2 16.1 7.7 44.5
2025 53.8 15.3 10.6 43.2
2026 66.3 20.4 12.3 54

Price Versus Our Estimated Value

Of the 16 fiscal years we can see for Electromed under its current filer, 13 show positive free cash flow.

At $22.98, Electromed trades above our fair value estimate of $6.60.

Free cash flow is volatile from year to year, with a variability measure of 106%.

No dividend yield is recorded for Electromed in our data.

These figures are automated calculations from SEC filings and the recent price. They are not a recommendation to buy or sell. See how we estimate value.

Compared With Its Sector and Industry

How to read this: the price to earnings ratio.

Its trailing P/E ratio is 16% below the average for stocks in the Healthcare sector.

Its trailing P/E ratio is in line with the average for stocks in the Medical Devices industry.

A P/E ratio depends on trailing earnings, which one-time items can distort, so a lower P/E is not by itself evidence of value.

Closest Industry Peers

These are companies in the Medical Devices industry, the ones closest in market capitalization to Electromed, limited to companies whose pages we publish. The figures come from our latest data for each company.

CompanyMarket cap (USD millions)P/EDividend yieldCash yieldPrice versus our estimate
Electromed (ELMD) 188 16.7 - - 248% above
Utah Medical Products (UTMD) 198 20.8 1.7% 6.7% 75% below
InfuSystem Holdings (INFU) 287 32.6 - - 402% above
Tactile Systems Technology (TCMD) 573 24.9 - - 162% above
IRadimed Corporation (IRMD) 1,036 43.3 1.0% - 995% above
CONMED Corporation (CNMD) 1,382 19.2 - 5.6% 35% below
LeMaitre Vascular (LMAT) 1,684 27.1 1.3% - 328% above

Industry labels are approximate, and companies in one industry can run quite different businesses, so a peer may not be a close match.

Ratios on different fiscal calendars are not strictly comparable, and a trailing P/E can be distorted by one-time items.

SEC Filer History

Every fiscal year on this page is reported by one SEC filer, CIK 1488917.

Each figure on this page comes from that filer.

Risks to This Analysis

How to read this: understanding investment risk.

  • Free cash flow was negative in 3 of the 16 years we have.
  • Free cash flow is volatile from year to year, so the estimates depend heavily on which years are included.
  • These figures are automated calculations from SEC filings and the recent price. They may contain errors, and they do not reflect lawsuits, management changes, or other events the filings do not show.

How This Page Is Made

Latest annual report used
Fiscal year 2026
Price and market data last refreshed
2026-11-20
Model assumptions last reviewed
2026-11-09

Company figures come from the annual reports (Form 10-K) that each company files with the SEC, read from the SEC EDGAR company facts data. The share price and other market data come from a market data provider.

Free cash flow here is operating cash flow minus capital spending. To keep one unusual year from swinging the result, each year is charged with the average of up to five years of capital spending, so the figure is an estimate and not the free cash flow a company reports.

The fair price is the present value of ten years of projected free cash flow plus a terminal value, discounted at 10.1 percent a year, the long-run return of US stocks, with 2.5 percent growth after year ten. The figures on this page are estimates, not advice.

This analysis covers US companies that file 10-K annual reports. Free cash flow describes banks, real estate investment trusts and funds poorly, so treat their figures with extra caution. In the cash returned and balance sheet tables, a value of zero is treated as a gap in the data, not as a real zero.

Read the filings yourself: ELMD annual reports (10-K) on SEC EDGAR. To try your own growth rate, use the intrinsic value calculator on this page. Our editorial standards explain how Trendshare handles its sources and corrections.

Advertisement supports free stock analysis content.

Questions to Answer Before You Invest in ELMD

Does Electromed have a coherent story? Does it have a plan to continue to make money? Is it worth your time? Only you can decide where to go from here. Our investment guide helps you ask the right questions, including how to buy stocks. Use these research links for more information.

Worked example: ELMD

This example shows how we apply the Trendshare checklist to ELMD: earnings power, cash generation, valuation, and margin of safety.

We check: business quality, free cash flow, P/E, and margin of safety.

  1. Step 1 — Snapshot

    • Price: 22.98
    • Market cap: $188M
    • EPS: 1.38
  2. Step 2 — Valuation checks

    • P/E: 16.652
    • FCF yield: —
    • Date checked: Nov 20, 2026
  3. Step 3 — Margin of safety

    • Compare price to fair value and safety price.
    • Look for durable cash generation and reasonable leverage.
    • Decide if it passes your personal checklist.